Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A08AA10
|
| gptkbp:CASNumber |
616202-92-7
|
| gptkbp:chemicalFormula |
C11H14ClN
|
| gptkbp:controlledSubstanceSchedule |
IV (US)
|
| gptkbp:eliminationHalfLife |
11 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:lorcaserin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Belviq
|
| gptkbp:legalStatus |
withdrawn
|
| gptkbp:manufacturer |
gptkb:Eisai
|
| gptkbp:mechanismOfAction |
serotonin 2C receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
X
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation dizziness fatigue headache dry mouth |
| gptkbp:usedFor |
weight loss
|
| gptkbp:withdrawn |
2020
increased cancer risk |
| gptkbp:bfsParent |
gptkb:Arena_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|